Regeneus Ltd (ASX:RGS) Potential Japan Licence Deal a STEP Closer
Regeneus Ltd (ASX:RGS) announce that an investment report by Edison titled "Potential Japan licence deal a STEP closer" has been published on the Regeneus website.
Companies in the News
Biotech
Regeneus Ltd (ASX:RGS) Australian Research Council Linkage Grant to Progress Stem Cell Research into Treating Chronic Pain
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today announced the Australian Research Council (ARC) had awarded a Linkage Grant of $340,000 to a research consortium that includes Regeneus collaborating with leading researchers from Macquarie University and the University of Adelaide.
Regeneus Ltd (ASX:RGS) Enrolment Complete and Positive Safety in Progenza Trial For Osteoarthritis
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced completion of enrolment of all 20 patients in the STEP trial. Further, a review of the cumulative study safety data by the study safety oversight committee identified no safety concerns.
The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
The Life Sciences Report: Advantage: Australia. Biotechs Surge Ahead in Regenerative Medicine and Immuno-Oncology
Regeneus Ltd (ASX:RGS) Appendix 4C - Quarterly
Regeneus Ltd (ASX:RGS) Achieved better than targeted net operating cash flow for the quarter. Cash outflow for the quarter was $1.44 million. Cash flow is tracking consistently better than the target of $1.70 million per quarter.
Orion Health (NZE:OHE) Builds Momentum in UK, Signs Contracts in England and Scotland
Orion Health (NZE:OHE) (ASX:OHE) has today announced it has signed two contracts that will significantly extend its presence in the United Kingdom. It will provide a comprehensive technology solution for two leading hospitals in London, and it will implement an integrated health and social care solution for NHS Fife in east Scotland.
iQ3Corp Ltd (ASX:IQ3) Appointment to Advise Investment Consortium Developing First in Class Novel Biologic Compound and Biomarker
iQ3Corp Ltd (ASX:iQ3) is pleased to announce that it has syndicated an investor consortium which include iQ Group Global entities, to enter into a joint venture to develop and commercialise a first in class oncology, novel biologic compound and biomarker.
◂Previous Page
Biotech Next Page▸
Banking & Finance
- VIDEO: Lion Selection Group Ltd (ASX:LSX) CEO Hedley Widdup and Sean Russo Talk at the Australian Gold Conference 2024
- VIDEO: The Australian Gold Conference 2024 - Education Evening with Expert Panel
- Lithium Universe Ltd (ASX:LU7) Finalises Frankfurt and US OTC Listing
Social Media
